Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes
POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or…
